West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China.
Department of Chemical Engineering, Imperial College London, London SW7 2AZ, United Kingdom.
ACS Sens. 2021 Jun 25;6(6):2108-2124. doi: 10.1021/acssensors.1c00669. Epub 2021 Jun 2.
Readily deployable, low-cost point-of-care medical devices such as lateral flow assays (LFAs), microfluidic paper-based analytical devices (μPADs), and microfluidic thread-based analytical devices (μTADs) are urgently needed in resource-poor settings. Governed by the ASSURED criteria (affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free, and deliverability) set by the World Health Organization, these reliable platforms can screen a myriad of chemical and biological analytes including viruses, bacteria, proteins, electrolytes, and narcotics. The Ebola epidemic in 2014 and the ongoing pandemic of SARS-CoV-2 have exemplified the ever-increasing importance of timely diagnostics to limit the spread of diseases. This review provides a comprehensive survey of LFAs, μPADs, and μTADs that can be deployed in resource-limited settings. The subsequent commercialization of these technologies will benefit the public health, especially in areas where access to healthcare is limited.
在资源匮乏的环境中，迫切需要易于部署且成本低廉的即时护理医疗设备，例如侧向流动检测（LFA）、微流控纸基分析器件（μPAD）和微流控线基分析器件（μTAD）。这些可靠的平台符合世界卫生组织（WHO）提出的 ASSURED 标准（负担得起、灵敏、特异、用户友好、快速和稳健、无需设备和交付能力），可用于筛查包括病毒、细菌、蛋白质、电解质和麻醉剂在内的各种化学和生物分析物。2014 年的埃博拉疫情和当前的 SARS-CoV-2 大流行，凸显了及时诊断对于限制疾病传播的重要性日益增加。本综述全面介绍了可在资源有限环境中部署的 LFA、μPAD 和 μTAD。这些技术的后续商业化将使公众受益，特别是在医疗保健服务有限的地区。
